 





<DOCTITLE>Opportunity For Licensing: Neutralizing Monoclonal Antibodies for Respiratory Syncytial Virus </DOCTITLE>



<AGENCY>
AGENCY:

 National Institutes of Health, Public Health Service, DHHS.

 

</AGENCY>
<ACTION>
ACTION:

 Notice. 






</ACTION>
<SUMMARY>
SUMMARY:

 The National Institutes of Health (NIH), Department of Health and Human Services (DHHS), seeks licensee(s) who can
effectively pursue the preclinical, clinical and commercial development of human monoclonal antibodies against
respiratory syncytial virus (RSV). NIH intends to grant the selected firm(s) world-wide royalty-bearing license(s)
to practice the inventions embodied in U.S. Patent Application SN 07/945,515 entitled ``Human Neutralizing Monoclonal
Antibodies for Respiratory Syncytial Virus'' and related foreign patent applications for all or some of the available
fields of use. The patent rights in these inventions have been jointly assigned to the United States of America and
The Scripps Research Institute.

 

</SUMMARY>
<SUPPLEM>
SUPPLEMENTARY INFORMATION:

 The NIH seeks licensee(s), who in accordance with requirements and regulations governing the licensing of government-owned
inventions (37 CFR part 404), have the most meritorious plan for the development of RSV monoclonal antibodies for
the treatment or prevention of RSV infections to a marketable status to meet the needs of the public and with the best
terms for the NIH. The criteria that NIH will use to evaluate license applications will include, but not be limited
to those set forth by 37 CFR 404.7(a)(1)(ii)-(iv).



</SUPPLEM>
<DATE>
DATES:

 In view of the high priority for developing prophylactics for the treatment of RSV infection, all proposals must be
received on or before July 27, 1994.



</DATE>
<ADDRESS>
ADDRESSES:

 Requests for a copy of the patent applications, license application form, or other questions and comments concerning
the licensing of this technology should be directed to: Mark D. Hankins Esq., Technology Licensing Specialist, Office
of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 208523804.
Telephone: (301) 4967735 ext. 265; Facsimile: (301) 4020220. 



A signed confidentiality agreement will be required to receive copies of the patent applications.

 


Dated: June 15, 1994. 


</ADDRESS>
<SIGNER>
Barbara M. McGarey, J.D.


</SIGNER>
<SIGNJOB>
Deputy Director, Office of Technology Transfer. 


</SIGNJOB>
<FRFILING>
[FR Doc. 9415470 Filed 62494; 8:45 am] 


</FRFILING>
<BILLING>
BILLING CODE 414001P 
</BILLING>



